TVG

The Vaccine Group (TVG) is a biotechnology company focused on developing next-generation vaccines to combat zoonotic and emerging infectious diseases in both humans and animals. A spin-out from the University of Plymouth, TVG utilizes a proprietary viral vector platform based on bovine herpesvirus 4 (BoHV-4) to induce potent and long-lasting immune responses. The company's technology is designed for rapid development and scalability, addressing global health threats such as COVID-19, Ebola, and Lassa fever. Additionally, TVG targets significant veterinary challenges, including African Swine Fever and bovine mastitis, to improve animal welfare and food security. The company collaborates extensively with international research institutions and government agencies to advance its diverse pipeline.